Related Experiment Video
Updated: May 19, 2026
05:21
A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Influenza immunization during pregnancy: US regulatory perspective
Valerie Marshall1, Marion Gruber
1Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA.
American Journal of Obstetrics and Gynecology
|August 28, 2012
Summary
Maternal immunization with inactivated influenza vaccines protects mothers and infants. New FDA regulations require prelicensure studies for specific pregnancy labeling of flu vaccines.
Area of Science:
- Immunology
- Public Health
- Vaccinology
Background:
- Maternal immunization with inactivated influenza vaccines is crucial for protecting pregnant individuals and infants from severe influenza complications.
- Currently, US-licensed influenza vaccines lack specific labeling for use during pregnancy, despite not being contraindicated.
- Ongoing postmarketing studies are gathering safety and immunogenicity data for inactivated influenza vaccines in pregnant women.
Purpose of the Study:
- To address the need for specific labeling of influenza vaccines for use during pregnancy.
- To inform the Food and Drug Administration's (FDA) revised pregnancy labeling regulations.
- To outline the requirements for obtaining a specifically labeled indication for maternal influenza vaccination.
Main Methods:
- Review of current regulatory status and ongoing postmarketing surveillance initiatives for influenza vaccines in pregnant populations.
- Analysis of the FDA's regulatory revision process for drug and biologic labeling during pregnancy.
- Identification of data requirements for prelicensure studies needed for specific pregnancy indications.
Main Results:
- US-licensed inactivated influenza vaccines are not specifically labeled for pregnancy, necessitating further investigation.
- The FDA is actively revising pregnancy labeling regulations to enhance risk communication.
- Adequate and well-controlled prelicensure studies demonstrating safety, effectiveness, and protection are required for specific pregnancy labeling.
Conclusions:
- Specific labeling for maternal influenza vaccination requires robust prelicensure data on safety and efficacy.
- Regulatory updates aim to improve the characterization and communication of risks associated with medications during pregnancy.
- Further research and clinical trials are essential to support the expanded use of influenza vaccines in pregnant individuals and infants.
Related Concept Videos
01:27Influenza
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:51Vaccinations
Overview
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...